“Time is of the essence”: physician challenges impact patient access to chimeric antigen receptor T-cell therapy

BACKGROUND: CD19-directed chimeric antigen receptor T-cell therapy (CART) is a life-saving regimen for children with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), yet children from lower socioeconomic and historically marginalized backgrounds are less likely to receive it. Understanding the provider experience of CART referral and post-CART clinical management is critical for designing effective interventions to improve access. OBJECTIVE: To explore physicians' experiences identifying and referring pediatric patients with r/r B-ALL for CART across diverse hospital settings, and to identify physician-perceived facilitators and barriers to CART treatment. STUDY DESIGN: Focus groups using a semi-structured guide were conducted with pediatric oncology physicians, recruited via email and at a national conference, with targeted recruitment of National Cancer Institute Community Oncology Research Program (NCORP) site providers. Questions explored identifying pediatric patients with r/r B-ALL as CART candidates, referring them for CART, and accessing institutional infrastructure to support referral. RESULTS: Analysis revealed six domains spanning referral to CART and subsequent CART treatment: identification of potentially eligible patients; complexity of CART referral; barriers to insurance approval; physician perception of patients' social/financial circumstances; and variability in pre- and post-CART management guidelines. Health system-level facilitators and barriers included patient identification and referral processes to tertiary care centers, guidelines for bridging therapy and post-CART toxicity management, and navigation support for patient care and insurance approval. CONCLUSION: Findings highlight challenges in community-based settings where resources, infrastructure and geographic availability for CART are variable. Standardizing referral pathways, centralizing trial information, and streamlining CART-center intake process and communication are of immediate importance.

Authors

Institutions

Publication Details

Journal
JNCI Cancer Spectrum
Published
2026-11-18
DOI
https://doi.org/10.1093/jncics/pkag123
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

“Time is of the essence”: physician challenges impact patient access to chimeric antigen receptor T-cell therapy

Susan Kenyon Parsons, Daniel J. Zheng, Kerry Q. Coughlin, Susan R. Rheingold et al.
2 links
JNCI Cancer Spectrum
CAR-T cell therapy research
article

“Time is of the essence”: physician challenges impact patient access to chimeric antigen receptor T-cell therapy

Susan Kenyon Parsons, Daniel J. Zheng, Kerry Q. Coughlin, Susan R. Rheingold, Haley M. Newman, Allison Barz Leahy, Shannon L. Maude, Anna Sparrow, Amanda M. DiNofia, Sarah Kathleen Tasian, Lucy E. Cain, Kira O'Neil Bona, Regina M. Myers, Stephen A. Grupp, Claire White, Melissa P Beauchamin, Colleen Kelly
article en

Abstract

BACKGROUND: CD19-directed chimeric antigen receptor T-cell therapy (CART) is a life-saving regimen for children with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), yet children from lower socioeconomic and historically marginalized backgrounds are less likely to receive it. Understanding the provider experience of CART referral and post-CART clinical management is critical for designing effective interventions to improve access. OBJECTIVE: To explore physicians' experiences identifying and referring pediatric patients with r/r B-ALL for CART across diverse hospital settings, and to identify physician-perceived facilitators and barriers to CART treatment. STUDY DESIGN: Focus groups using a semi-structured guide were conducted with pediatric oncology physicians, recruited via email and at a national conference, with targeted recruitment of National Cancer Institute Community Oncology Research Program (NCORP) site providers. Questions explored identifying pediatric patients with r/r B-ALL as CART candidates, referring them for CART, and accessing institutional infrastructure to support referral. RESULTS: Analysis revealed six domains spanning referral to CART and subsequent CART treatment: identification of potentially eligible patients; complexity of CART referral; barriers to insurance approval; physician perception of patients' social/financial circumstances; and variability in pre- and post-CART management guidelines. Health system-level facilitators and barriers included patient identification and referral processes to tertiary care centers, guidelines for bridging therapy and post-CART toxicity management, and navigation support for patient care and insurance approval. CONCLUSION: Findings highlight challenges in community-based settings where resources, infrastructure and geographic availability for CART are variable. Standardizing referral pathways, centralizing trial information, and streamlining CART-center intake process and communication are of immediate importance.

JNCI Cancer Spectrum
Tufts Medical Center (US), Children's Hospital of Philadelphia (US), Harvard University (US), Columbia University Irving Medical Center (US), Penn Center for AIDS Research (US), Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US), Herbert Irving Comprehensive Cancer Center (US), University of Pennsylvania (US)
U.S. Department of Defense, Conquer Cancer Foundation, Pennsylvania Department of Health, Children's Hospital of Philadelphia, National Institutes of Health, National Cancer Institute, National Institute on Minority Health and Health Disparities
Good health and well-being, Reduced inequalities
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon